Items Tagged ‘brentuximab’

March 22, 2018

FDA Approves Adcetris® in Combination with Chemotherapy for Previously Untreated Stage III or IV Classical Hodgkin Lymphoma

By

CancerConnect News: The U.S. Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) in combination with chemotherapy in adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma. The approval is based on the successful outcome of the ECHELON-1 clinical trial that compared Adcetris plus AVD (Adriamycin, vinblastine and dacarbazine) to ABVD […]

View full entry

Tags: adcetris, brentuximab, classical, hodgkin lymphoma, Hodgkin's Lymphoma, News, Precision Cancer Medicine, vedotin


March 1, 2018

Addition of the Precision Cancer Medicine Adcetris Reduces the Risk of Treatment Failure in Advanced Hodgkin Lymphoma

By

CancerConnect News: Patients with advanced Hodgkin lymphoma (HL) who were treated with a multi-drug regimen that included the precision cancer medicine Adcetris (brentuximab vedotin) had a 23-percent reduction in the risk of disease progression, death, or the need for additional therapy, compared with patients who received the standard treatment for advanced HL.1 Hodgkin’s lymphoma is […]

View full entry

Tags: ABVD, adcetris, brentuximab, hodgkin lymphoma, Hodgkin's Lymphoma, News, Precision Cancer Medicine, vedotin


November 15, 2017

Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)

By

-MF and pcALCL Represent the Most Common Subtypes of Cutaneous T-Cell Lymphoma (CTCL)- -FDA Approval Based on Clinical Trial Results from the Phase 3 ALCANZA and Phase 2 Investigator-Sponsored Studies in CTCL- “Cutaneous T-cell lymphoma is a blood cancer of the skin with no known cure and few new treatment options. It is a disfiguring […]

View full entry

Tags: adcetris, brentuximab, Cutaneous Anaplastic Large Cell Lymphoma, mycosis fungoides, News, Non-Hodgkin's Lymphoma, pcALCL, vedotin